Baxdrostat
CIN-107AZ's aldosterone synthase inhibitor for resistant hypertension. Three completed P3s with readouts pending; one P3 in primary aldosteronism still recruiting.
Emerging drug — Phase 3 readout — POSITIVE
✓ Won · Read out 2025-07-14BaxHTN met primary + all secondary endpoints: 15.7 mmHg absolute SBP reduction at week 12, placebo-adjusted 9.8 mmHg (95% CI -12.6 to -7.0; p<0.001). Hot Line presentation ESC Congress 2025; simultaneous NEJM publication. Bax24 trial also positive (14.0 mmHg ambulatory SBP reduction).
Regulatory: NDA accepted under FDA Priority Review
Next remaining catalyst
AwaitingA positive readout makes CYP11B2 a validated target for the first time. Hover the badge above for what the confidence level means.
What does it do?
CYP11B2 — Aldosterone synthase (cytochrome P450 11B2)
Modality: small-molecule selective aldosterone synthase inhibitor
Program: BaxHTN
The 4 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT06034743 | Uncontrolled Hypertension; Resistant Hypertension | 796 | COMPLETED | 2023-11-22 | 2025-05-21 (actual) | Awaiting |
| NCT06168409 | Resistant Hypertension | 218 | COMPLETED | 2024-03-01 | 2025-08-17 (actual) | Awaiting |
| NCT06344104 | Uncontrolled Hypertension; Resistant Hypertension | 326 | COMPLETED | 2024-04-08 | 2025-11-24 (actual) | Awaiting |
| NCT07007793 | Primary Hyperaldosteronism | 250 | RECRUITING | 2025-08-07 | 2028-02-18 | Fresh est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2023 | acquisition | CinCor Pharma | $1.8B |
What's the case for and against?
✓ What's working in its favor
- Phase 2 BrigHTN: -11 mmHg vs placebo at 12 weeks (resistant HTN)
- First selective CYP11B2 inhibitor to reach Phase 3 with avoidance of cortisol synthesis (CYP11B1) cross-reactivity
Who else is racing? — 3 other assets at CYP11B2
| Asset | Sponsor | Status |
|---|---|---|
| Lorundrostat | Mineralys Therapeutics | P3 active |
| Dexfadrostat | Damian Pharma | P2 primary aldosteronism |
| QLS1410 | Qilu (China) | P1 |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.